Literature DB >> 16384873

Intestinal alkaline phosphatase gene expression is activated by ZBP-89.

Madhu S Malo1, Moushumi Mozumder, Xiao Bo Zhang, Shaluk Biswas, Alexander Chen, Long-Chuan Bai, Juanita L Merchant, Richard A Hodin.   

Abstract

Intestinal alkaline phosphatase (IAP) is an enterocyte differentiation marker that functions to limit fat absorption. Zinc finger binding protein-89 (ZBP-89) is a Kruppel-type transcription factor that appears to promote a differentiated phenotype in the intestinal epithelium. The purpose of this study was to investigate the regulation of IAP gene expression by ZBP-89. RT-PCR, quantitative real-time RT-PCR, Western blot analyses, and reporter assays were used to determine the regulation of IAP by ZBP-89 in HT-29 and Caco-2 colon cancer cells. ZBP-89 knockdown was achieved by specific short interfering (si)RNA. EMSA and chromatin immunoprecipitation (ChIP) were performed to examine the binding of ZBP-89 to the IAP promoter. The results of RT-PCR, quantitative real-time PCR, and Western blot analyses showed that ZBP-89 was expressed at low levels in Caco-2 and HT-29 cells, whereas IAP was minimally expressed and absent in these cells, respectively. Transfection with ZBP-89 expression plamid increased IAP mRNA and protein levels in both cell lines, whereas knockdown of endogenous ZBP-89 by siRNA reduced basal levels of IAP gene expression in Caco-2 cells. IAP-luciferase reporter assays, EMSA, and ChIP established that ZBP-89 activated the IAP gene through a response element (ZBP-89 response element: 5'-CCTCCTCCC-3') located between -1018 and -1010 bp upstream of the AUG start codon. We conclude that ZBP-89 is a direct transcriptional activator of the enterocyte differentiation marker IAP. These findings are consistent with the role that this transcription factor is thought to play as a tumor suppressor and suggests its possible function in the physiology of fat absorption.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16384873     DOI: 10.1152/ajpgi.00394.2005

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  9 in total

Review 1.  Recent advances in small bowel diseases: Part II.

Authors:  Alan B R Thomson; Angeli Chopra; Michael Tom Clandinin; Hugh Freeman
Journal:  World J Gastroenterol       Date:  2012-07-14       Impact factor: 5.742

2.  Expression of transcription factor zinc-binding protein-89 (ZBP-89) is inhibited by inflammatory cytokines.

Authors:  Ruth C Borghaei; Mariah Chambers
Journal:  Pathol Lab Med Int       Date:  2009-08-01

3.  Twenty-one-base-pair insertion polymorphism creates an enhancer element and potentiates SLC6A1 GABA transporter promoter activity.

Authors:  Rungnapa Hirunsatit; Elizabeth D George; Barbara K Lipska; Hani M Elwafi; Lisa Sander; Carolyn M Yrigollen; Joel Gelernter; Elena L Grigorenko; Jaakko Lappalainen; Shrikant Mane; Angus C Nairn; Joel E Kleinman; Arthur A Simen
Journal:  Pharmacogenet Genomics       Date:  2009-01       Impact factor: 2.089

4.  The intestinal epithelial cell differentiation marker intestinal alkaline phosphatase (ALPi) is selectively induced by histone deacetylase inhibitors (HDACi) in colon cancer cells in a Kruppel-like factor 5 (KLF5)-dependent manner.

Authors:  Joongho Shin; Azadeh Carr; Georgia A Corner; Lars Tögel; Mercedes Dávalos-Salas; Mercedes Dávaos-Salas; Hoanh Tran; Anderly C Chueh; Sheren Al-Obaidi; Fiona Chionh; Naseem Ahmed; Daniel D Buchanan; Joanne P Young; Madhu S Malo; Richard A Hodin; Diego Arango; Oliver M Sieber; Leonard H Augenlicht; Amardeep S Dhillon; Thomas K Weber; John M Mariadason
Journal:  J Biol Chem       Date:  2014-07-18       Impact factor: 5.157

5.  ZBP-89 reduces the cell death threshold in hepatocellular carcinoma cells by increasing caspase-6 and S phase cell cycle arrest.

Authors:  George G Chen; Ursula P F Chan; Long-Chuan Bai; King Yip Fung; Art Tessier; Ann K Y To; Juanita L Merchant; Paul B S Lai
Journal:  Cancer Lett       Date:  2009-04-11       Impact factor: 8.679

6.  Intestinal Alkaline Phosphatase Deficiency Is Associated with Ischemic Heart Disease.

Authors:  Jagannath Malo; Md Jahangir Alam; Munjareen Shahnaz; Kanakaraju Kaliannan; Gopal Chandra; Tarek Aziz; Tapas Sarker; Mihir Bala; Ratna Paul; Chandan K Saha; Pradip K Karmakar; Madhu S Malo
Journal:  Dis Markers       Date:  2019-12-13       Impact factor: 3.434

7.  Comparative analysis of the mammalian WNT4 promoter.

Authors:  Hongshi Yu; Andrew J Pask; Geoffrey Shaw; Marilyn B Renfree
Journal:  BMC Genomics       Date:  2009-09-06       Impact factor: 3.969

8.  A High Level of Intestinal Alkaline Phosphatase Is Protective Against Type 2 Diabetes Mellitus Irrespective of Obesity.

Authors:  Madhu S Malo
Journal:  EBioMedicine       Date:  2015-12-01       Impact factor: 8.143

9.  IIAEK Targets Intestinal Alkaline Phosphatase (IAP) to Improve Cholesterol Metabolism with a Specific Activation of IAP and Downregulation of ABCA1.

Authors:  Asahi Takeuchi; Kentaro Hisamatsu; Natsuki Okumura; Yuki Sugimitsu; Emiko Yanase; Yoshihito Ueno; Satoshi Nagaoka
Journal:  Nutrients       Date:  2020-09-18       Impact factor: 5.717

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.